SIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical

Stock News

08/15

SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.

According to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1113120887"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113120887\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113120887?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113120887","market":"fut","top_or_hot":-1,"title":"SIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical","media":"Stock News","content":"<p>SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.</p>\n<p>According to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-08-15 19:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.</p>\n<p>According to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"醫美概念股","start_time":0,"source_url":"","article_id":"1113120887","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113120887","pubTimestamp":1755258019,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1593":"医美概念股","BK1600":"工业大麻","BK1515":"抗疫概念","00460":"四环医药","BK1191":"制药"},"translate_title":"四环医药(00460)：NMPA受理惠升生物制药研发的司美格鲁肽注射液上市申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.\nAccording to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}